3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
2
Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumors Harboring NTRK Fusion
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Pemetrexed
18
Carboplatin
16
Cisplatin
14
Paclitaxel
9
Gemcitabine
7
pembrolizumab
6
Crizotinib
5
osimertinib
4
amivantamab
4
Nivolumab
4
Docetaxel
4
lazertinib
3
Vinorelbine
3
Ipilimumab
3
Afatinib
3
selpercatinib
2
lorlatinib
2
durvalumab
2
cemiplimab
2
atezolizumab
2
alectinib
2
Gefitinib
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zenocutuzumab
1
trastuzumab deruxtecan
1
trametinib
1
tepotinib
1
telisotuzumab vedotin
1
taletrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma, Non-Small-Cell Lung
×
larotrectinib
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA